Analyzing AbbVie (NYSE:ABBV) and Neuphoria Therapeutics (NASDAQ:NEUP)

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Volatility & Risk

Neuphoria Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.

Insider and Institutional Ownership

15.9% of Neuphoria Therapeutics shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 1.5% of Neuphoria Therapeutics shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Neuphoria Therapeutics and AbbVie’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuphoria Therapeutics N/A -38.31% -28.92%
AbbVie 15.67% -450.55% 16.50%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Neuphoria Therapeutics and AbbVie, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuphoria Therapeutics 1 2 0 0 1.67
AbbVie 0 6 22 1 2.83

Neuphoria Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 176.68%. AbbVie has a consensus target price of $297.85, indicating a potential downside of 0.29%. Given Neuphoria Therapeutics’ higher possible upside, research analysts plainly believe Neuphoria Therapeutics is more favorable than AbbVie.

Valuation & Earnings

This table compares Neuphoria Therapeutics and AbbVie”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Neuphoria Therapeutics $1.17 million 11.66 -$13.45 million ($6.22) -0.41
AbbVie $61.16 billion 8.63 $4.23 billion $5.81 51.41

AbbVie has higher revenue and earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Summary

AbbVie beats Neuphoria Therapeutics on 10 of the 15 factors compared between the two stocks.

About Neuphoria Therapeutics

(Get Free Report)

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions. The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies. Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

About AbbVie

(Get Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Receive News & Ratings for Neuphoria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.